¹Ù·Î°¡±â ¸Þ´º
¸ÞÀθ޴º ¹Ù·Î°¡±â
º»¹®³»¿ë ¹Ù·Î°¡±â
  • HOME
  • ·Î±×ÀÎ
  • ȸ¿ø°¡ÀÔ
  • ¼¼¸í±âµ¶º´¿ø ȨÆäÀÌÁö ¹Ù·Î°¡±â
Ȩ¹öư Home > ¾àÁ¦°ú ¼Ò½Ä > ÃֽŠÀÇÇÐ Á¤º¸

ÃֽŠÀÇÇÐ Á¤º¸

Ãֽž๰Á¤º¸ (FDA ½ÂÀÎ ¾à¹° 2013.12-2014.2)

°Ô½ÃÀÏ 2014-03-18 09:16
Anoro Ellipta (umeclidinium and vilanterol inhalation powder); GlaxoSmithKline; For the maintenance treatment of chronic obstructive pulmonary disease, Approved December of 2013
Sovaldi (sofosbuvir); Gilead Sciences; For the treatment of hepatitis C, December of 2013
Xiaflex (collagenase clostridium histolyticum); Auxilium; For the treatment of Peyronie's disease, Approved December of 2013
Tretten (Coagulation Factor XIII A-Subunit [Recombinant]); Novo Nordisk; For the treatment of congenital factor XIII (FXIII) A-subunit deficiency, Approved December of 2013
Farxiga (dapagliflozin); Bristol-Myers Squibb; For the treatment of type II diabetes, January of 2014
Myalept (metreleptin for injection); Bristol-Myers Squibb; For the treatment of congenital or acquired generalized lipodystrophy, Approved February of 2014
Northera (droxidopa); Chelsea Therapeutics; For the treatment of neurogenic orthostatic hypotension, Approved February 2014
Tivorbex (indomethacin); Iroko Pharmaceuticals; For the treatment of acute pain, Approved February of 2014
Vimizim (elosulfase alfa); BioMarin; For the treatment of Mucopolysaccharidosis type IVA, Approved February 2014
Imbruvica (ibrutinib); Pharmacyclics; For the treatment of chronic lymphocytic leukemia, Approved February 2014
Hetlioz (tasimelteon); Vanda Pharmaceuticals; For the treatment of non-24-hour sleep-wake disorder in the totally blind, January 2014
ÄÚ¸àÆ® 0|Á¶È¸ 1,355
°Ô½Ã¹° ³»¿ë ÀμâÇϱâÀμâ| ÃÖÈñ¿µ
  • ¸ñ·Ï
  • ¾²±â
´ñ±Û´Þ±â
À̸§   ÀÎÁõºñ¹ø   ÀÚµ¿È®ÀιæÁö ÀÚµ¿¹æÁöŰ

¹®¼­Æò°¡/¹®¼­´ã´çÀÚ

[37816] °æºÏ Æ÷Ç׽à ³²±¸ Æ÷½ºÄÚ´ë·Î 351 (´ëµµµ¿ 94-5) ¼¼¸í±âµ¶º´¿ø ´ëÇ¥ÀüÈ­ 054-275-0005

copyright 2014 semyung gidok hospital. all rights reserved